Bulletins - Administration
Filter by category:
AdministrationAdverse drug reactionsComplementary and Alternative Medicines (CAMs)COVID-19Drug comparisonsInteractionsNew medicineOtherPharmacokineticPregnancy/Breastfeeding


Empagliflozin and dulaglutide in type 2 diabetes - April 6, 2021
NZ is funding two medicines in new classes for the treatment of type 2 diabetes.1 These will be second line options after metformin, and favoured for patients at high risk of cardiovascular or renal complications. They are subject to special authority criteria.1-3 Empagliflozin, a sodium-glucose ...



Oral Anticoagulants – Rivaroxaban and Dabigatran - October 1, 2019
Rivaroxaban (Factor Xa inhibitor), dabigatran etexilate (direct thrombin inhibitor), or warfarin (vitamin K epoxide reductase inhibitor) can be used as oral anticoagulants for most indications. Warfarin remains first line for patients with mechanical heart valves or severe chronic kidney disease....



Repackaging dabigatran into compliance packs - October 8, 2018
Compliance packs
With an ageing population there is increasing incidence of multimorbidity and polypharmacy. This leads to complex dosing regimens.
Compliance aids, such as the Medico Paks® or unit dose medication sachets, are widely used to manage complex medication regimes, and help remind...